Diabetic kidney disease is a major cause of chronic kidney condition and the most common complication of diabetes. The cellular senescence participates in the process of diabetic kidney disease, but the specific mechanism is not yet clear. Cell cycle-related protein E2F transcription factor 1 (E2F1) is a member of the E2F transcription factor family, it plays a key role in cellular damage under HG conditions. In this study, we explored whether metformin improves a high-glucose-induced senescence and fibrosis of renal tubular epithelial cells through cell cycle-related protein E2F1. In the in vivo experiments, the recombinant adeno-associated virus (AAV-shE2F1) knockdown E2F1 gene was injected into the tail vein of 16-weeks-old db/db mice for 8 weeks. The 16-week-old db/db mice were administered metformin (260 mg/kg/d) continuously for 8 weeks. The normal control group (NC) and diabetic model group (DM) were set up simultaneously. Mice renal tubular epithelial cells (mRTECs) were cultured in vitro. The cells were randomly divided into the following groups: normal glucose (NG, containing 5.5 mmol/L glucose), high glucose group (HG, containing 30 mmol/L glucose), NG/HG metformin intervention group (NG/HG + Met), NG/HG negative control siRNA transfection group (NG/HG + Control), NG/HG E2F1 siRNA transfection group (NG/HG + siRNA E2F1), HG metformin intervention and overexpression E2F1 plasmid transfection group (HG + Met + overexpress-E2F1). The expression of related indexes were detected by Western blot, real-time polymerase chain reaction (PCR), immunohistochemistry, and immunofluorescence. The results showed that E2F1 knockdown or metformin reduces the degree of renal fibrosis, DNA damage, and cellular senescence in the DM group; metformin also reduced the expression of E2F1. If E2F1 was overexpressed, the effects of metformin in delaying fibrosis and reducing DNA damage and cellular senescence could be weakened. Thus, metformin alleviates high-glucose-induced senescence and fibrosis of renal tubular epithelial cells by downregulating the expression of E2F1.

Keywords: metformin, diabetic kidney disease, DNA damage, renal tubular epithelial cells, fibrosis, E2F1
INTRODUCTION

Aging leads to physiological senescence in an organism, followed by various diseases that further facilitate cellular senescence. The senescent cells accumulate and damage various tissues and organs (Kirkland and Tchkonia, 2017), thus causing loss of function of the body. The production of senescent cells can be triggered by a variety of diseases, such as atherosclerosis, diabetes (Childs et al., 2015), osteoarthritis, and glaucoma (Calcinoatto et al., 2019). If these senescent cells are not eliminated promptly, it would further affect the progression of the disease. Obesity and age are the major factors endangering type 2 diabetes, and both increase the burden of cells and promote cellular senescence (Palmer et al., 2019). Especially, obesity increases the level of senescence-associated markers, such as senescence-associated β-galactosidase (SA-β-Gal) activity and the production of senescence-associated secretory phenotype (SASP), such as proinflammatory cytokines interleukin-6 (IL-6) and tumor necrosis factor-α (TNF-α); the level of these inflammatory cytokines accelerate the senescence of neighboring cells (Burton and Faragher, 2018). The study demonstrated that hyperglycemia causes the thickening of the glomerular basement membrane, the extracellular matrix (ECM) alteration, and renal tubulointerstitial fibrosis (Bdra et al., 2020). In recent years, the role of cellular senescence in DKD has gained increasing attention. Hyperglycemia accelerates the aging of glomerular mesangial cells and renal tubular epithelial cells and induces the secretion of SASP components, thus promoting inflammation and cellular senescence (Xiong and Zhou, 2019). Since the mechanisms of cellular senescence are complex, exploring its role in DKD would provide critical clues for treatment.

Metformin is a cost-effective and highly safe biguanide derivative widely used in cancer, cardiovascular disease, and kidney disease. It is one of the most commonly used drugs for the treatment of type 2 diabetes (Lv and Guo, 2020). Under the condition of high glucose, the survival rate of human umbilical vein endothelial cells decreased, and oxidative stress and chromosomal abnormalities occurred, indicating that diabetes hyperglycemia can interfere with the biochemical or biophysical properties of endothelial cells (Rezabakhsh et al., 2017). Moreover, high glucose also significantly reduced the viability of human umbilical vein endothelial cells and inhibited cell migration, while metformin significantly improved these characteristics, and promoted the angiogenic potential of endothelial cells, regulated the dynamics of endothelial cells under high glucose conditions, and improved the development of diabetic foot ulcers (Zolali et al., 2019). Furthermore, metformin alleviates the development of DKD by inhibiting the deposition of ECM and inflammation of glomerular mesangial cells by regulating the H19/miR-143-3p/TGF-β1 signaling pathway (Xu et al., 2020). It also reduces the production of oxidative stress during DKD through AMPK/SIRT1-FoxO1 pathway, enhances the autophagy response in the early stage of DKD, and reduces renal tubulointerstitial fibrosis (Ren et al., 2019; Wang et al., 2021). Metformin also exerts effects on diabetic retinopathy, aging, and cancer through mechanisms beyond nonapoptotic cell death, immunosuppression, and AMPK pathways (Hsu et al., 2021). In addition, metformin has a regulatory role in the renal aging process of DKD and delays the progress of DKD by reducing cellular senescence. Also, an active role is effectuated in high-glucose-induced renal tubular epithelial cells and db/db mice model through the MBNL1/miR-130a-3p/STAT3 pathway (jiang et al., 2020). Metformin also reduces the loss of podocytes, mesangial cell apoptosis, and renal tubular epithelial cell senescence through the AMPK signal transduction pathway and exerts a renal protective role in DKD (Song et al., 2021). The anti-inflammatory and anti-fibrosis mechanisms of metformin and alleviation of cellular senescence in DKD are yet to be elucidated. Therefore, exploring the potential mechanism between metformin, DKD, and cellular senescence underlying the progression of DKD development is imperative.

Cell cycle-related protein E2F1 is a member of the E2F transcription factor family. It is involved in several biological processes, such as DNA damage response, cell migration and invasion, differentiation, metabolism, and cell cycle regulation (Roworth et al., 2015; Liang et al., 2016). E2F1 leads to hyperlipidemia and hyperglycemia in DM. Thus, inhibiting E2F1 activity prevents the hyperglycemia caused by obesity (Giralt et al., 2018). In the case of high glucose, the knockout of E2F1 gene can save high-glucose-induced neuronal cell death (Wang et al., 2017). In addition, the regulatory effect of E2F1 on the cell cycle suggested a regulatory effect of E2F1 on cellular senescence. Moreover, P21 and P16, potent inhibitors of cell cycle-dependent kinase (CDK), blocked the phosphorylation of CDK-dependent retinoblastoma (RB) phosphorylation, leading to E2F1 inhibition and cell cycle arrest (Dick and Rubin, 2013). In addition, the overexpression of E2F1 induces senescence of normal cells (Xie et al., 2014). However, in human cancer cells, the expression of senescence markers increased after transfection with a small interference RNA (siRNA) to knock down the expression of E2F1 (Park et al., 2006). Together, these studies suggested that the regulation of E2F1 on cellular senescence is complex and unknown, and DKD is yet to be investigated.

In this study, we proved that high glucose causes renal tubular epithelial cell senescence by elevating the expression of E2F1, and metformin effectuates anti-fibrosis, reducing DNA damage response and anti-renal tubular epithelial cell aging by downregulating the expression of E2F1.

MATERIALS AND METHODS

DM Mouse Model Groups
A total of 30 specific pathogen-free (SPF) grade male db/db mice, 7-week-old, weighing 40 ± 5 g and 10 non-transgenic db/m mice with the same background at the same age, weighing 20 ± 5 g were
provided by GemPharmatech Co., Ltd. The batch number is BSK-DB T002407. The 7-week-old db/db mice comprised the normal control (NC) group. db/db mice were randomly and equally divided into DM group, AAV-shE2F1, and metformin (Met) groups. The mice were fed SPF grade feed, allowed pure water drinking *ad libitum*, and maintained at an appropriate temperature, humidity, and 12 h/day light. The AAV-shE2F1 group was injected the adeno-associated virus carrying the E2F1 knockdown gene [Obio Technology (Shanghai) Corp. Ltd.] through the tail vein at week 16. The dose for each mouse was $2.4 \times 10^{11}$ VG/ml. The Met group was treated with metformin (Sino American Shanghai Squib Pharmaceutical Ltd.) by gavage at a dose of 260 mg/kg/d for 6 days/week and continuously for 8 weeks. All mice ate and drank water normally and were sacrificed at week 24. Mice urine, fasting serum, and kidney tissues were collected for the subsequent studies.

**Detection of Biochemical Indexes of Mice**

Blood glucose (BG) was measured using the glucose oxidase method. Blood urea nitrogen (BUN) was measured using the urease continuous monitoring method. Serum creatinine (S-CRE) was measured via the oxidase method. Triglyceride (TG) was measured using the phosphoglycerol oxidase method. Urinary microalbumin was measured using the phenol-sulfuric acid method. Albumin (Alb) was measured using the Alami method. Blood glucose (BG) was measured using the glucose oxidase method. Blood urea nitrogen (BUN) was measured using the urease continuous monitoring method. Serum creatinine (S-CRE) was measured via the oxidase method. Triglyceride (TG) was measured using the phosphoglycerol oxidase method. Urinary microalbumin was measured by enzyme-linked immunosorbent assay (ELISA).

**Histopathological Observation of Mice Kidney Tissues**

The renal tissue sections were fixed with 4% neutral formaldehyde, embedded in paraffin, and stained with hematoxylin-eosin (HE), periodic acid Schiff (PAS), Masson, and Sirius red after dewaxing. The pathomorphological changes of renal tissue sections in the different groups of mice were observed under an ordinary optical microscope (OLYPMUS, Japan).

**Cell Culture, Transfection, and Administration**

mRTEC cell line was obtained from Otwo Biotech Inc. (Catalogue No: HTX2460), and cultured in medium (DME/M; Gibco, United States, low glucose, containing 5.5 mmol/L glucose) containing 10% fetal bovine serum (FBS; Biological Industries, Israel) in a constant temperature incubator under 5% CO$_2$ at 37°C. At 90% confluency, the cells were subcultured and used in subsequent experiments. E2F1 siRNA (Jima, Shanghai) and E2F1 overexpression plasmid (Yi le Biotech, Shanghai) were transfected into mRTECs, respectively. The negative control siRNA was transfected into the normal glucose/high glucose empty group (NG/HG + Control), the E2F1 siRNA was transfected into the normal glucose/high glucose knockdown group (NG/HG + siRNA E2F1). The cells cultured in normal glucose medium (5.5 mmol/L) and high glucose medium (30 mmol/L) containing 10% FBS were plated in a six-well plate for 72 h, followed by whole-protein extraction for subsequent experiments. Cell counting kit-8 (CCK-8; APEX BIO, United States) assay was used to detect the proliferation ability of mRTECs cultured in high-glucose after metformin (MedChemExpress, United States) intervention concentrations 10, 50, 100, and 150 μmol/L. The concentration of 50 μmol/L with maximal proliferation ability was selected for mRTEC intervention. Then, the cells were randomly divided into five groups: normal glucose/high glucose group (NG/HG), normal glucose/high glucose metformin intervention group (NG/HG + Met), high glucose metformin intervention and overexpression E2F1 plasmid transfection group (HG + Met + overexpress-E2F1) and cultured for 72 h for further experimental studies.

**Western Blot**

Mice renal cortical proteins were extracted and subjected to acrylamide gel electrophoresis. The proteins were detected by incubation with rabbit anti-E2F1 (Abcam, ab112580, 1:1,000), rabbit anti-ATM (Abdsin, ab131163, 1:1,000), rabbit anti-p-ATM (Abdsin, ab140239, 1:1,000), rabbit anti-Chk2 (Bioss, bs-1391R, 1:1,000), rabbit anti-p-Chk2 (Bioss, bs-3721R, 1:1,000), rabbit anti-P21 (Proteintech, 10355-1-AP, 1:1,000), rabbit anti-Fibronectin (Abcam, ab2413, 1:1,000), rabbit anti-Collagen III (Proteintech, 22734-1-AP, 1:1,000), and β-actin antibody-horseradish peroxidase (HRP)-conjugated (PMK, PMK058S, 1:5,000) antibodies at 4°C overnight. The next day, the polyvinylidene fluoride (PVDF; Millipore, United States) membranes were incubated with secondary antibodies at room temperature for 1 h and visualized by Smart-ECL (Beyotime Biotechnology, Shanghai) chemiluminescence solution, and the immunoreactive bands were analyzed quantitatively by Image J software.

**Real-Time Polymerase Chain Reaction**

Total RNA was extracted from mice renal cortex using TRIzol reagent (Ambion, Thermo, United States) and reverse transcribed into complementary DNA (cDNA). E2F1, P21, Fibronectin, and β-actin were amplified using cDNA as the template, with β-actin as an internal reference. The relative expression of E2F1, P21, and Fibronectin mRNA was calculated with the $2^{-\Delta\Delta Ct}$ method and analyzed statistically. The primer sequences (Biotech Co., Ltd.) were as follows: E2F1: Forward: 5'-GAGAAGTCCGGCCTATGAAACCTC-3', Reverse: 5'-CCCAGTTCAGGTCAACGACAC-3'; annealing temperature 55.3°C; P21: Forward: 5'-TGTTCTGACACTCTGGTGTCG-3', Reverse: 5'-ATCTGGCCTTGGAGTTGATAAG-3'; annealing temperature 55.6°C; Fibronectin: Forward: 5'-GTCCTGAGCTACCAACCTC-3', Reverse: 5'-GCAGGAGTTGTGATGACACC-3'; annealing temperature 55.8°C; β-actin: Forward: 5'-GTGTCCATTGAACCAACCT-3'; Reverse: 5'-GCTGCTCAACACCATGACC-3'; annealing temperature 58.5°C.

**Immunofluorescence of Kidney Tissue Sections**

The tissue sections were dewaxed in double distilled water (ddH$_2$O) before the antigen was retrieved by heating in citric
acid in a microwave oven. Then, the sections were blocked with 3% hydrogen peroxide to remove endogenous catalase, permeabilized with 0.5% Triton X-100, washed with phosphate-buffered saline (PBS), blocked with 5% bovine serum albumin (BSA) at room temperature for 1 h, and incubated with mouse anti-E2F1 antibody (1:50) and mouse anti-P21 antibody (1:50) at 4 °C overnight, followed by incubation with Cy3 antibody (1:200) at 37°C in the dark for 1 h. The nucleus was stained with DAPI (Solarbio, Beijing, China), and the tissue sections were sealed with an anti-fluorescence quencher, observed, and photographed under a fluorescence microscope (OLYPUMS, Japan).

**Cellular Immunofluorescence**

The cells were cultured in six-well plates and divided into groups according to the experiments. After the intervention, the cells were fixed with 4% paraformaldehyde, permeabilized with 0.5% TritonX-100, washed with PBS, and blocked with 10% BSA at 37°C for 30 min. The other steps were the same as those of tissue immunofluorescence.
**Immunohistochemistry**

The procedure of tissue section dewaxing to hydrogen peroxide blocking was the same as that of tissue immunofluorescence, followed by PBS washes. Then, the sections were incubated with mouse anti-E2F1 antibody (1:50) and rabbit anti-Fibronectin antibodies (1:50) at 4°C overnight, followed by incubation with goat anti-mouse/rabbit IgG-labeled with HRP at room temperature for 20 min. Subsequently, the sections were stained with DAB [Gene Technology (Shanghai) Co., Ltd., GK500705]. The nucleus was stained with hematoxylin, dehydrated, sealed with neutral resin, observed, and photographed under an optical microscope.

**β-Galactosidase Staining**

The staining procedure was carried out according to the instructions of the kit (Cell Signaling Technology). After sealing, the sections were observed and imaged captured under the optical microscope.

**Enzyme-Linked Immunosorbent Assay**

The content of TNF-α and IL-6 in mouse tissue supernatant was detected using the Elabscience kit.

**Network Pharmacology Analysis**

The targets of metformin were obtained through relevant databases. The relevant targets of DKD were screened from the GeneCards database. The Venn diagram program obtained the putative targets of drugs for disease treatment. Metascape platform was used to annotate the intersecting proteins through gene ontology (GO). Protein-protein interaction (PPI) pathways were used to analyze the intersection proteins using the STRING database and Cytoscape software.

**Statistical Analysis**

The Western blot images were analyzed by Image J software. The experimental data were analyzed by SPSS 25.0 software and expressed as mean ± standard deviation (SD); one-way ANOVA was used for comparison among multiple groups, LSD test was used for comparison between the two groups, \( p < 0.05 \) indicated a statistically significant difference.

**RESULTS**

**Results of Network Pharmacology**

In order to identify the targets of metformin in the treatment of DKD, we retrieved 366 coincident targets of metformin and DKD from the database (Figure 1A). These coincident targets are putative targets of metformin in the treatment of DKD. The PPI network diagram was constructed for all proteins at the
intersection (Figure 1B). The results of the GO enrichment analysis showed that biological processes, such as aging and DNA damage, were involved in identifying the potential targets of metformin in the treatment of DKD (Figure 1C). Therefore, the PPI network diagram of this process was constructed separately (Figure 1D). The core targets include ATM, Chk2, CDKN1A (P21), CDKN1B, MDM2, and TP53. Finally, the altered expression of P21, ATM, and Chk2 was observed in the subsequent experiments. Then, bioinformatics was utilized to identify the proteins that directly interact with E2F1. These were combined with the network pharmacology prediction targets and E2F1 interaction protein to construct the PPI network diagram (Figure 1E). The results showed that E2F1 was directly involved in the process of DNA damage in the treatment of DKD with metformin.

### Changes in the Biochemical Indexes of Mice in Each Group

Compared to the NC group, BG, TG, T-CHO, S-CRE, BUN, and urine microalbumin levels were significantly increased in the DM group. (Table 2, Figures 3A-L).
group. Compared to the DM group, the above indexes in the Met group showed an opposite trend, the levels of BG, BUN, and urine microalbumin were significantly decreased in the AAV-shE2F1 group, the levels of TG, cholesterol-CHO and S-CRE were no significant changes. (p < 0.05; Table 1).

Pathomorphological Changes in the Renal Tissue in Each Group
The results of PAS staining showed that the basement membrane of glomerulus and renal tubules was significantly thickened in the DM group compared to the NC group, and the mesangial area was accompanied by cell proliferation. The results of HE staining showed that the glomerulus and renal tubules of the NC group mice had complete structure and regular morphology, while those of the DM group had glomerulosclerosis, renal tubular atrophy, and epithelial cell abscession. Masson and Sirus red staining showed that collagen fibers were deposited in the renal interstitium of the DM group, while the above pathological changes were alleviated in the AAV-shE2F1 and Met groups (Figure 2).

Metformin Improves the Process of Renal Fibrosis and the Degree of DNA Damage and Cellular Senescence in the High-Glucose State
Western blot results showed that the protein expression levels of Fibronectin and COL III were significantly higher in the DM group than in the NC group (Figure 3A). Immunohistochemical staining and real-time PCR results showed that the protein and mRNA levels of Fibronectin were significantly higher in the DM group than in the NC group (Figures 3B,C). After metformin intervention, the expression of the above indexes decreased markedly. Compared to the NG group, the levels of Fibronectin and COL III proteins were significantly higher in the HG group, compared to the HG group, the levels of Fibronectin and COL III proteins were significantly lower in the HG + Met group (Figure 3D). The results of Western blot showed that the phosphorylation levels of DNA damage-related indexes ATM and Chk2 were significantly increased in vitro and in vivo in the
high-glucose environment. The Metformin intervention significantly decreased the expression of the above indexes (Figures 3E,F). Western blot, real-time PCR, and tissue immunofluorescence showed that the level of P21 was higher in the DM group than in the NC group (Figures 3G–I). According to ELISA, the content of IL-6 and TNF-α was increased markedly in the DM group (Table 2), after metformin intervention, the expression of the above indexes decreased markedly. Western blot and cellular immunofluorescence results showed that the expression of P21 was significantly higher in the HG group than the NG group and decreased significantly in the HG + Met group (both \( p < 0.05 \); Figures 3J,K). Interestingly, the β-galactosidase-positive staining was significantly more in the HG group than the NG group but significantly reduced in the HG + Met group (Figure 3L). These results suggested that metformin improves the process of renal fibrosis in the high-glucose state, reduces the degree of DNA damage, and delays cellular senescence.

High Expression of E2F1 in Renal Tubular Epithelial Cells in the High-Glucose State

Western blot, tissue immunofluorescence, immunohistochemical staining, and real-time PCR showed significantly higher expression of E2F1 in the DM group than the NC group (Figures 4A–D). Western blot and cellular immunofluorescence results showed that the expression of E2F1 was significantly higher in the HG group than in the NG group (\( p < 0.05 \); Figures 4E,F).
High Expression of E2F1 Promotes the Fibrosis of Renal Tubular Epithelial Cells in the High-Glucose State

Western blot showed that the levels of Fibronectin and COL III proteins were significantly higher in the DM group than in the NC group (Figure 5A). Immunohistochemical staining and real-time PCR revealed that the protein and mRNA levels of Fibronectin were significantly higher in the DM group than those in the NC group (Figures 5B,C). However, the expression of the above indexes was significantly decreased in the AAV-shE2F1 group. Compared to the NG + Control and NG + siRNA E2F1 groups. The protein levels of Fibronectin and COL III were significantly higher in the HG group and significantly lower in the HG + siRNA E2F1 group (p < 0.05; Figure 5D). Thus, the high expression of E2F1 can promote the fibrosis of renal tubular epithelial cells in the high-glucose state and downregulating the expression can improve the process of fibrosis.

High Expression of E2F1 Promotes Cellular Senescence of Renal Tubular Epithelial Cells in the High-Glucose State

Western blot, real-time PCR, and tissue immunofluorescence showed that the expression of P21 was significantly higher in the DM group than the NC group and lower in the AAV-shE2F1 group (Figures 7A–C). The results of ELISA revealed that the content of IL-6 and TNF-α was higher in the DM group and significantly lower in the AAV-shE2F1 group than in the NC group (Table 3). Compared to the NG + Control and NG + siRNA E2F1 groups, the level of P21 protein was significantly higher in the HG group and significantly lower in the HG + siRNA E2F1 group (p < 0.05; Figure 7D). This phenomenon suggested that the high expression of E2F1 promotes the senescence of renal tubular epithelial cells in the high-glucose state.

Metformin Improves Renal Injury in the High-Glucose State Through E2F1

Compared to the NG group, the expression of E2F1, Fibronectin, and COL III, the phosphorylation levels of ATM and Chk2, and the expression of P21 was significantly increased in the HG group. After the intervention with metformin, the expression of the above indexes decreased, and the consequent overexpression of E2F1 weakened the effect of metformin on the above indexes in mRTECs (Figures 8A,B, p < 0.05). Thus, the anti-fibrosis, anti-senescence, and DNA damage repair effects of metformin in the high-glucose state were achieved by downregulating the expression of E2F1.
DISCUSSION

P16 expression and SA-β-Gal activity increased in renal tubular epithelial cells, podocytes, mesangial cells, and endothelial cells in patients with type 2 DKD (Verzola et al., 2008). Also, cellular senescence markers were produced in mesangial cells cultured in vitro with high glucose (Zhang et al., 2006) and streptozotocin-induced mice model of type 1 diabetes (Kitada et al., 2014). These results suggested that hyperglycemia is a key driver of cellular senescence and may contribute to DKD progression. Accumulating evidence showed that cellular senescence might be involved in the pathophysiological process of DKD. A large
A number of studies reported the putative mechanism of cellular senescence in DKD (Chen et al., 2018; Yi-Chun et al., 2018). However, because the pathogenesis of DKD and cellular senescence is complex, the correlation and regulatory mechanism between DKD and cellular senescence need to be explored further. In the current study, we used db/db mice model in the in vivo experiments, and the model is a widely used animal model of type 2 DKD. It is a leptin receptor mutation that causes abnormal splicing and adipocyte-derived hormone leptin receptor defects, and the leptin receptor deficiency affects the hypothalamic reaction, which makes the mice appear hyperappetite, obese, hyperlipidemia, and insulin resistant, and the other symptoms are similar to those of patients with type 2 diabetes (Tesch and Lim, 2011). The results of this experiment showed that BG, TG, T-CHO, S-CRE, BUN, and urine microalbumin were significantly increased in db/db mice compared to db/m mice. HE and PAS staining revealed that the glomerular basement membrane of db/db mice was thickened, the mesangial area was accompanied by apparent mesangial cell proliferation, the morphology of renal tubules was irregular, and the epithelial cells of renal tubules were detached. Masson and Sirus red staining showed fibrosis in renal tubulointerstitium. All the above results are consistent with the characteristics of DKD, indicating that type 2 diabetes progressed to DKD in the db/db mice model.

Metformin is the most widely used oral hypoglycemic drug, which reduces DKD by inhibiting renal inflammation, oxidative stress, and fibrosis (Kawanami et al., 2020). It also reduces the senescence of renal tubular epithelial cells induced by high glucose, inhibiting high-glucose-induced renal lesions, and plays a renal protective role in DKD (Jiang et al., 2020). Herein, we searched the database to retrieve the putative targets of metformin in the treatment of DKD, involved in aging and DNA damage; the core targets include ATM, CHK2, P21, CDKN1B, MDM2, and TP53. We focused on the altered P21, ATM, and CHK2 expression in renal tubular epithelial cells in the high-glucose state. After 8 weeks of in vivo intervention in db/db mice, the results showed that metformin reduces BG, TG, T-CHO, S-CRE, BUN, and urinary microalbumin. It could also improve the pathomorphological changes of db/db mice. The expression of Fibronectin, COL III, and P21 proteins was decreased in the renal cortex of db/db mice, and inhibited the phosphorylation levels of ATM and Chk2, while the content of IL-6 and TNF-α in renal supernatant of db/db mice was reduced. This finding suggested that metformin improves the degree of renal tissue fibrosis, inflammation, DNA damage, and cellular senescence in DKD.

E2F1 is involved in cell cycle regulation, apoptosis signal transduction, cell growth, metastasis, autophagy, and other processes (Yuan et al., 2018). The study demonstrated the specific biological function of E2F1 in the progression and related complications of DM. It also promotes hyperlipidemia and hyperglycemia in DM by directly controlling hepatic...
gluconeogenesis (Giralt et al., 2018). In recent years, the role of E2F1 in cellular senescence has been under intensive focus (Gao et al., 2019). So what is the role of E2F1 in the cellular senescence in DKD? Thus, we used bioinformatics to identify the proteins acting directly with E2F1. The results suggested that E2F1 is directly involved in DNA damage and cellular senescence with respect to the treatment of DKD with metformin. Hence, we injected the adeno-associated virus carrying the E2F1 knockdown gene into db/db mice through the tail vein; animals were sacrificed after 8 weeks. Consequently, the levels of BG, BUN, and urinary microalbumin of adeno-associated virus mice injected with knockdown E2F1 gene were significantly lower than those of db/db mice, the levels of TG, cholesterol-CHO and S-CRE were no significant changes. Moreover, the pathological morphology was improved, and the indexes related to fibrosis, DNA damage, and cellular senescence were reduced, while the levels of IL-6 and TNF-α were significantly reduced in the supernatant of renal tissue. Interestingly, the decrease in E2F1 alleviates the degree of renal tissue fibrosis, the level of inflammation, and the senescence of renal tubular epithelial cells in DKD. In addition, metformin reduces the expression level of E2F1 in the renal tissue of db/db mice. To further confirm that E2F1 is directly involved in metformin-alleviated fibrosis, DNA damage, and cellular senescence in DKD, we stimulated mRTECs with high glucose in vitro and found that the indexes related to E2F1, fibrosis, DNA damage, and cellular senescence increased significantly, but decreased after transfection with E2F1 siRNA. This phenomenon suggested that the increase in E2F1 affects the occurrence of fibrosis and cellular senescence in DKD, which is consistent with the results in vivo. Moreover, the stimulation of mRTECs with high glucose and metformin demonstrated that metformin reduces the expression of E2F1 in the high-glucose state and reverses the increased collagen and fibronectin levels, DNA damage, and senescence-associated markers. Therefore, it could be deduced that metformin exerts an anti-fibrosis role and delays cellular senescence by reducing the expression of E2F1 in the high-glucose state. In order to test this hypothesis, we overexpressed E2F1 after metformin treatment in the high-glucose state. Compared to the metformin treatment alone group, the anti-fibrosis and delayed cell senescence effects of metformin after overexpression of E2F1 were significantly weakened. Together with the in vivo results, it was confirmed that metformin is a renal anti-fibrosis and cell aging agent in DKD via decreased expression of E2F1 in the high-glucose state.

In conclusion, the current results suggested that metformin has a protective effect on high glucose-induced renal tubular epithelial cell injury. The mechanism is to reverse the degree of fibrosis of DKD renal tissue, reduce DNA damage, and slow down the aging process of renal tubular epithelial cells by reducing the expression of E2F1. Thus, this study provided a new experimental basis for the mechanism of metformin in renal protection in DKD. It also provides new drug targets for delaying the process and treatment of renal fibrosis and cellular senescence in DKD.

**DATA AVAILABILITY STATEMENT**

The original contributions presented in the study are included in the article/Supplementary Materials. further inquiries can be directed to the corresponding authors.

**ETHICS STATEMENT**

The animal study was reviewed and approved by Animal Experimental Ethical Inspection Form of Guizhuo Medical University.

**AUTHOR CONTRIBUTIONS**

DL and ZL contributed significantly to the work, obtained the main experimental data, analyzed and interpreted the results, and wrote the manuscript. ZF, YD and XW: Assisted in the acquisition and analysis of some experimental data. ZY, FZ, YW, YZ, LL and MS: Reviewed the results and revised manuscript. YIX and BG designed and directed the Experiment, and assured the feasibility of the Experiment.

**FUNDING**

This study was supported by the National Natural Science Foundation of China (Grant Nos. 81860656 and 81860135) and the Guizhou Province Science and Technology Foundation (Grant Nos. Guizhou Science and Technology Foundation-ZK [2021] Focus 010).

**REFERENCES**

Burton, D. G. A., and Faragher, R. G. A. (2018). Obesity and Type-2 Diabetes as Inducers of Premature Cellular Senescence and Ageing. Biogerontology 19 (6), 447–459. doi:10.1007/s10522-018-9763-7

Calcinoatto, A., Kohli, J., Zagato, E., Pellegrini, L., Demaria, M., and Alimonti, A. (2019). Cellular Senescence: Aging, Cancer, and Injury. Physiol. Rev. 99 (2), 1047–1078. doi:10.1152/physrev.00290.2018

Chen, K., Dai, H., Yuan, J., Chen, J., Lin, L., Zhang, W., et al. (2018). Optineurin-mediated Mitophagy Protects Renal Tubular Epithelial Cells against Accelerated Senescence in Diabetic Nephropathy. Cell Death Dis. 9 (2), 105. doi:10.1038/s41419-017-0127-z

Childs, B. G., Durik, M., Baker, D. J., and van Deursen, J. M. (2015). Cellular Senescence in Aging and Age-Related Disease: from Mechanisms to Therapy. Nat. Med. 21 (12), 1424–1435. doi:10.1038/nm.4000

Dick, F. A., and Rubin, S. M. (2013). Molecular Mechanisms Underlying RB Protein Function. Nat. Rev. Mol. Cell Biol. 14 (5), 297–306. doi:10.1038/nrm3567

Gao, S., Song, Q., Liu, J., Zhang, X., Ji, X., and Wang, P. (2019). E2F1 Mediates the Downregulation of POLD1 in Replicative Senescence. Cell Mol. Life Sci. 76 (14), 2833–2850. doi:10.1007/s00018-019-03070-z

Giralt, A., Denexchaud, P. D., Lopez-Mejia, I. C., Delacuisine, B., Blanchet, E., Bonner, C., et al. (2018). E2F1 Promotes Hepatic Gluconeogenesis and Contributes to Hyperglycemia during Diabetes. Mol. Metab. 11, 104–112. doi:10.1016/j.molmet.2018.02.011

Childs, B. G., Durik, M., Baker, D. J., and van Deursen, J. M. (2015). Cellular Senescence in Aging and Age-Related Disease: from Mechanisms to Therapy. Nat. Med. 21 (12), 1424–1435. doi:10.1038/nm.4000

Dick, F. A., and Rubin, S. M. (2013). Molecular Mechanisms Underlying RB Protein Function. Nat. Rev. Mol. Cell Biol. 14 (5), 297–306. doi:10.1038/nrm3567

Gao, S., Song, Q., Liu, J., Zhang, X., Ji, X., and Wang, P. (2019). E2F1 Mediates the Downregulation of POLD1 in Replicative Senescence. Cell Mol. Life Sci. 76 (14), 2833–2850. doi:10.1007/s00018-019-03070-z

Giralt, A., Denexchaud, P. D., Lopez-Mejia, I. C., Delacuisine, B., Blanchet, E., Bonner, C., et al. (2018). E2F1 Promotes Hepatic Gluconeogenesis and Contributes to Hyperglycemia during Diabetes. Mol. Metab. 11, 104–112. doi:10.1016/j.molmet.2018.02.011
Hsu, S. K., Cheng, K. C., Mbgeahuruie, M. O., Lin, Y. H., Wu, C. Y., Wang, H. D., et al. (2021). New Insight into the Effects of Metformin on Diabetic Retinopathy, Aging and Nonapoptotic Cell Death, Immunosuppression, and Effects beyond the AMPK Pathway. *Int. J. Mol. Sci.* 22 (17), 9453. doi:10.3390/ijms22179453

Jiang, X., Ruan, X. L., Xue, Y. X., Yang, S., Shi, M., Wang, L. N., et al. (2020). Metformin Reduces the Senescence of Renal Tubular Epithelial Cells in Diabetic Nephropathy via the MBNL1/miR-130a-3p/STAT3 Pathway. *Oxid. Med. Cell Longev.* 2020 (6), 8708236–8708322. doi:10.1155/2020/8708236

Kawanami, D., Takashi, Y., and Tanabe, M. (2020). Significance of Metformin Use in Diabetic Kidney Disease. *Int. J. Mol. Sci.* 21 (12), 4239. doi:10.3390/ijms21124339

Kirkland, J. L., and Tchkonia, T. (2017). Cellular Senescence: a Translational Perspective. *Ebiomedicine* 21 (C), 21–28. doi:10.1016/j.ebiom.2017.04.013

Kitada, K., Nakano, D., Ohskai, H., Hitomi, H., Minamino, T., Yatabe, J., et al. (2014). Hyperglycemia Causes Cellular Senescence via a SGLT2- and P21-dependent Pathway in Proximal Tubules in the Early Stage of Diabetic Nephropathy. *J. Diabetes Complicat.* 28 (5), 604–611. doi:10.1016/j.jdiacomp.2013.05.010

Kumar, V., Agrawal, R., Pandey, A., Kopf, S., Hoeflgein, M., Kaymak, S., et al. (2020). Compromised DNA Repair Is Responsible for Diabetes-Associated Fibrosis. *EMBO J.* 39 (11), e103477. doi:10.15252/embj.2019103477

Liang, Y. X., Lu, J. M., Mo, R. J., He, H. C., Xie, J., Jiang, F. N., et al. (2016). E2F1 Promotes Tumor Cell Invasion and Migration through Regulating CD47 in Prostate Cancer. *Int. J. Oncol.* 48 (4), 1650–1658. doi:10.3892/ijo.2016.3364

Lv, Z., and Guo, Y. (2020). Metformin and its Benefits for Various Diseases. *Front. Endocrinol. (Lausanne)* 11, 191. doi:10.3389/fendo.2020.00191

Palmer, A. K., Gustafson, B., Kirkland, J. L., and Smith, U. (2019). Cellular Senescence: at the Nexus between Ageing and Diabetes. *Diabetologia* 62 (10), 1835–1841. doi:10.1007/s00125-019-4934-x

Park, C., Lee, I., and Kang, W. K. (2006). E2F-1 is a Critical Modulator of Cellular Senescence in Human Cancer. *Int. J. Mol. Med.* 17 (5), 715–720. doi:10.3892/ijmm.17.5.715

Poppy Roworth, A., Ghari, F., and La Thangue, N. B. (2015). To live or let die - Senescence in Human Cancer. *Mol. Cell Oncol.* 8708322. doi:10.1155/2020/8708236

Xu, B.-H., Sheng, J., You, Y.-K., Huang, X.-R., Ma, R. C. W., Wang, Q., et al. (2020). Deletion of Smad3 Prevents Renal Inflammation and Inflammation in Type 2 Diabetic Nephropathy. *Metabolism* 103, 15013. doi:10.1016/j.metabol.2019.15013

Xu, J., Xiang, P., Liu, S., and Ye, S. (2020). Metformin Inhibits Extracellular Matrix Accumulation, Inflammation and Proliferation of Mesangial Cells in Diabetic Nephropathy by Regulating H19/miR-143-3p/TGF-B1 axis. *J. Pharm. Pharmacol.* 72 (8), 1101–1109. doi:10.1111/jpp.13280

Yi-Chun, T., Kuo, P. L., Kuo, M. C., Hung, W. W., Wu, L. Y., Chang, W. A., et al. (2018). The Interaction of miR-378i-Skp2 Regulates Cell Senescence in Diabetic Nephropathy. *J. Clin. Med.* 7 (12), 468. doi:10.3390/jcm7120468

Yuan, Y., Li, X., and Li, M. (2018). Overexpression of miR-17-5p P-rotects against H-igh G-lucose-induced E-nothelial C-ell I-njury by T-argeting E2F1-mediated S-pression of A-utophagy and P-romotion of A-poptosis. *Int. J. Mol. Med.* 42 (3), 1559–1568. doi:10.3892/ijmm.2018.3697

Zhang, X., Chen, X., Wu, D., Liu, W., Wang, J., Feng, Z., et al. (2006). Down-regulation of Connexin 43 Expression by High Glucose Induces Senescence in Glomerular Mesangial Cells. *J. Am. Soc. Nephrol.* 17 (6), 1532–1542. doi:10.1681/ASN.20050707762

Zolali, E., Rezabakhsh, A., Nabat, E., Jaber, H., Rahbarghazi, R., and Garjani, A. (2019). Metformin Effect on Endocan Biogenesis in Human Endothelial Cells under Diabetic Condition. *Arch. Med. Res.* 50 (5), 304–314. doi:10.1016/j.arcmed.2019.08.012

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

**Publisher’s Note:** All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Liang, Li, Feng, Yuan, Dai, Wu, Zhang, Zhou, Liu, Shi, Xiao and Guo. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is which does not comply with these terms.